Longer-acting anti-VEGF
Faricimab and high-dose aflibercept for retinal disease.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 3, 9, 13, 20, 26.
All papers from the last 12 months
428 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- Early high-dose aflibercept 8 mg clinical outcomes in wet age-related macular degeneration patients resistant to aflibercept 2 mg or faricimabActa Ophthalmol2026 NovPMID 42544785
- Efficacy of Intravitreal Faricimab for Diabetic Macular Edema and Analysis of Influencing FactorsOphthalmologica2026 Oct 16PMID 42886638
- When Retention Becomes an Outcome: Disentangling Faricimab Durability and Care AccessClin Exp Ophthalmol2026 Oct 16PMID 42885654
- When Retention Becomes an Outcome: Disentangling Faricimab Durability and Care Access-ResponseClin Exp Ophthalmol2026 Oct 15PMID 42880723
- Variables Associated With Faricimab Treatment Durability in Neovascular Age-Related Macular Degeneration: A Post Hoc Analysis of the TENAYA and LUCERNE TrialsJAMA Ophthalmol2026 Oct 15PMID 42879146
- Epivascular Glia and Macular Pigment Changes after Faricimab or Aflibercept during the Loading Phase in Diabetic Macular Edema: A Prospective Non-randomized Pilot StudyPhotodiagnosis Photodyn Ther2026 Oct 14PMID 42874754
- Switching to faricimab in anti-VEGF-refractory retinal vein occlusion: nine-month prospective real-world outcomes under a modified treat-and-extend regimenGraefes Arch Clin Exp Ophthalmol2026 Oct 13PMID 42867512
- The Clinical Significance of Polypoidal Lesion Regression in Polypoidal Choroidal Vasculopathy - A ReviewSemin Ophthalmol2026 Oct 11PMID 42860692Review
- Study Design for ELARA, a Phase 3b Trial of Aflibercept 8 mg in Previously Treated Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular EdemaOphthalmol Ther2026 Oct 9PMID 42853354
- Comparative Clinical and Therapeutic Landscape of Aflibercept Biosimilars (YESAFILI), High-Dose Aflibercept 8 mg (EYLEA HD), and Faricimab (VABYSMO): A Structured Narrative ReviewClin Ophthalmol2026PMID 42866554Review
More ophthalmology trends
All specialties →Myopia control in children
Atropine drops, defocus lenses and orthokeratology to slow myopia.
Key point: In myopic children, atropine efficacy increased nonlinearly with concentration and may plateau, while higher doses were associated with decreased accommodation and photophobia.
Ischaemic optic neuropathy
Non-arteritic anterior ischaemic optic neuropathy, including reports linked to GLP-1 drugs.
Key point: In acute NAION, increased early optic nerve head swelling rates were associated with visual field and visual acuity worsening by month 6.
AI in retinal imaging
Deep learning on fundus photos and OCT, including signs of systemic disease.
Diabetic retinopathy screening
Screening for diabetic retinopathy, including autonomous AI.
Gene therapy for inherited retinal disease
Gene therapy and optogenetics for inherited retinal dystrophies.
Minimally invasive glaucoma surgery
MIGS devices and procedures.
Key point: Phaco-iStent and phaco-KDB both significantly reduced intraocular pressure and glaucoma medication burden with few postoperative complications.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
faricimab[tiab] OR "aflibercept 8"[tiab] OR "high-dose aflibercept"[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.